Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 313.50
Bid: 305.00
Ask: 310.50
Change: 11.00 (3.64%)
Spread: 5.50 (1.803%)
Open: 313.00
High: 313.50
Low: 313.00
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

3 Jul 2023 07:00

RNS Number : 6507E
Oxford Biomedica PLC
03 July 2023
 

 

 

 

Oxford Biomedica

Total Voting Rights

 

 

Oxford, UK - 3 July 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company's issued share capital as at the close of business on 30 June 2023 consisted of 96,580,639 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 96,580,639.

 

The above figure (96,580,639) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAKXAELEDEFA
Date   Source Headline
9th May 20087:00 amRNSInterim Management Statement
30th Apr 200811:42 amRNSTotal Voting Rights
15th Apr 20087:00 amRNSBoard changes
3rd Apr 20088:35 amRNSAnnual Information Update
1st Apr 20084:18 pmRNSMajor Interest in Shares
31st Mar 200810:48 amRNSTotal Voting Rights Update
25th Mar 200810:06 amRNSNew Trovax Clinical Data
18th Mar 20089:09 amRNSMajor Interest in Shares
17th Mar 200812:32 pmRNSPresentation at Conference
13th Mar 200812:26 pmRNSDirectors' Interest in Shares
10th Mar 20088:52 amRNSBoard Appointment
10th Mar 20087:02 amRNSPhase III Trist Study
10th Mar 20087:01 amRNSPreliminary Results
29th Feb 200811:43 amRNSTotal Voting Rights Update
20th Feb 20087:00 amRNSPhase III Trist Study
19th Feb 20084:22 pmRNSHolding(s) in Company
15th Feb 20089:05 amRNSMajor Interest In Shares
13th Feb 200812:15 pmRNSMajor Interest in Shares
7th Feb 20087:00 amRNSNotification of Results
1st Feb 200810:40 amRNSNotification of Shares
31st Jan 20088:57 amRNSTotal Voting Rights
30th Jan 20088:00 amRNSNotifcation of Shares
23rd Jan 20089:16 amRNSMajor Interest in Shares
22nd Jan 20087:00 amRNSDevelopment Milestone
18th Jan 200812:53 pmRNSNotification of Shares
7th Jan 20087:00 amRNSExclusive License Agreement
18th Dec 20071:35 pmRNSInterest In Shares
13th Dec 20077:00 amRNSPhase I/II Trial
10th Dec 200712:28 pmRNSMajor Interest in Shares
10th Dec 20077:00 amRNSTrovax Phase III Trial
5th Dec 20071:33 pmRNSScrip's Deal of the year
29th Nov 200710:51 amRNStechMARK Award
16th Nov 200711:18 amRNSBlock Listing
9th Nov 20077:00 amRNSBroker Announcement
26th Oct 20077:01 amRNSPatent Infringement Dispute
25th Oct 200711:27 amRNSDirector/PDMR Shareholding
25th Oct 20077:01 amRNSBusiness Update
22nd Oct 20072:57 pmRNSDirector Shareholdings
28th Sep 20073:25 pmRNSHolding(s) in Company
11th Sep 20077:00 amRNSMilestone in Trovax
11th Sep 20077:00 amRNSInterim Results
31st Aug 20073:39 pmRNSHolding(s) in Company
31st Aug 200710:26 amRNSTVR Update
30th Aug 20079:10 amRNSHolding(s) in Company
7th Aug 20077:00 amRNSNotice of Results
3rd Aug 20074:33 pmRNSHolding(s) in Company
2nd Aug 20073:38 pmRNSHolding(s) in Company
2nd Aug 20077:02 amRNSPhase II Clinical Trial Data
31st Jul 20073:05 pmRNSTotal Voting Rights
25th Jul 20077:00 amRNSDSMB Interim Analysis-TroVax

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.